Radiotherapy for salivary gland cancer: REFCOR recommendations by the formal consensus method.
Hadrontherapy
Radiotherapy
Salivary gland cancer
Journal
European annals of otorhinolaryngology, head and neck diseases
ISSN: 1879-730X
Titre abrégé: Eur Ann Otorhinolaryngol Head Neck Dis
Pays: France
ID NLM: 101531465
Informations de publication
Date de publication:
28 Nov 2023
28 Nov 2023
Historique:
medline:
30
11
2023
pubmed:
30
11
2023
entrez:
29
11
2023
Statut:
aheadofprint
Résumé
To determine the indications for radiotherapy in salivary gland cancer and to specify the modalities and target radiation volumes. The French Network of Rare Head and Neck Tumors (REFCOR) formed a steering group which drafted a narrative review of the literature published on Medline and proposed recommendations. The level of adherence to the recommendations was then assessed by a rating group, according to the formal consensus method. Postoperatively, radiotherapy to the primary tumor site±to the lymph nodes is indicated if one or more of the following adverse histoprognostic factors are present (risk>10% of locoregional recurrence): T3-T4 category, lymph node invasion, extraglandular invasion, close or positive surgical margins, high tumor grade, perineural invasion, vascular emboli, and/or bone invasion. Intensity-modulated radiation therapy (IMRT) is the gold standard. For unresectable cancers or inoperable patients, carbon ion hadrontherapy may be considered. Radiotherapy in salivary gland cancer is indicated in postoperative situations in case of adverse histoprognostic factors and for inoperable tumors.
Identifiants
pubmed: 38030445
pii: S1879-7296(23)00158-8
doi: 10.1016/j.anorl.2023.11.006
pii:
doi:
Types de publication
Practice Guideline
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 Elsevier Masson SAS. All rights reserved.